Product Description: CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C13H13N3S
References: [1]Lai CY, et, al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine. 2014 Sep 29;32(43):5593-9./[2]Spranger S, et, al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010 Jul 1;185(1):738-47./[3]Maalej KM, et, al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. J Leukoc Biol. 2015 Jun;97(6):1081-7.
CAS Number: 256922-53-9
Molecular Weight: 243.33
Compound Purity: 99.25
Research Area: Inflammation/Immunology
Solubility: DMSO : 22 mg/mL (ultrasonic;warming)
Target: Toll-like Receptor (TLR)
Deutsch
English
